
-
Stock markets mixed as uncertainty rules ahead of Trump tariffs
-
China probes for key target weak spots with 'paralysing' Taiwan drills
-
'Top Gun' and Batman star Val Kilmer dies aged 65: New York Times
-
US lawmakers seek to rename street for Hong Kong's jailed Jimmy Lai
-
Greece to spend big on 'historic' military shake up
-
Trump faces first electoral setback after Wisconsin Supreme Court vote
-
Hay shines as New Zealand beat Pakistan for ODI series win
-
Israel says expands Gaza offensive to seize 'large areas'
-
Curry drops 52 as Warriors win, Jokic bags career-high 61 in Denver loss
-
South Korea mobilising 'all resources' for violence-free Yoon verdict
-
Myanmar quake victim rescued after 5 days as aid calls grow
-
Real Madrid coach Ancelotti tax fraud trial set to begin
-
Warner showcases 'Superman' reboot, new DiCaprio film
-
'Incredible' Curry scores 52 as Warriors down Grizzlies, Bucks edge Suns
-
Asian markets edge up but uncertainty rules ahead of Trump tariffs
-
Nintendo's megahit Switch console: what to know
-
Nintendo to unveil upgrade to best-selling Switch console
-
China practises hitting key ports, energy sites in Taiwan drills
-
Oil, sand and speed: Saudi gearheads take on towering dunes
-
All eyes on Tsunoda at Japan GP after ruthless Red Bull move
-
'Image whisperers' bring vision to the blind at Red Cross museum
-
Hay shines as New Zealand make 292-8 in Pakistan ODI
-
Other governments 'weaponising' Trump language to attack NGOs: rights groups
-
UK imposes online entry permit on European visitors
-
How a Brazilian chief is staving off Amazon destruction
-
Meme politics: White House embraces aggressive alt-right online culture
-
China launches military drills in Taiwan Strait
-
US senator smashes record with 25-hour anti-Trump speech
-
Brazil binman finds newborn baby on garbage route
-
US senator smashes record with marathon anti-Trump speech
-
Trump advisor Waltz faces new pressure over Gmail usage
-
Niger junta frees ministers of overthrown government
-
Trump set to unleash 'Liberation Day' tariffs
-
Boeing chief to acknowledge 'serious missteps' at US Senate hearing
-
Real Madrid hold Real Sociedad in eight-goal thriller to reach Copa del Rey final
-
Nuno salutes 'special' Elanga after stunning strike fires Forest
-
PSG survive scare against Dunkerque to reach French Cup final
-
Sundowns edge Esperance as crowd violence mars quarter-final
-
Nottingham Forest beat Man Utd, Saka scores on Arsenal return
-
Elanga wonder-goal sinks Man Utd as Forest eye Champions League berth
-
Stock markets mostly advance ahead of Trump tariffs deadline
-
US movie theaters urge 45-day 'baseline' before films hit streaming
-
Saka scores on return as Arsenal beat Fulham
-
Third-division Bielefeld shock holders Leverkusen in German Cup
-
Ball-blasting 'Torpedo bats' making waves across MLB opening weekend
-
Newsmax shares surge more than 2,000% in days after IPO
-
Thousands of Hungarians protest against Pride ban law
-
GM leads first quarter US auto sales as tariffs loom
-
Tesla sales tumble in Europe in the first quarter
-
No 'eye for an eye' approach to US tariffs: Mexico

Mice trial raises hopes for 'on demand' male contraceptive
If women have the "morning after" pill, could men one day have an "hour before" pill?
A new drug candidate renders male mice infertile within an hour and wears off in less than a day, an experimental study said Tuesday, potentially pointing towards a future "on-demand" male contraceptive.
The potential drug, which has not been tested in humans and remains years away from possibly becoming available, joins a growing number of male contraceptives in development.
However there are currently only two options available for men: condoms and vasectomies.
Previous drugs have struggled partly because the bar for side effects is believed to be far higher for men -- because they do not risk getting pregnant -- as well as a lack of interest from the pharmaceutical industry.
"For women, right now all the burden of contraception is on us," Melanie Balbach, a pharmacology researcher at Weill Cornell Medicine in the US, told AFP.
"We want new options," said Balbach, the lead author of the study published in Nature Communications.
The team of researchers targeted an enzyme called soluble adenylyl cyclase, which acts as the "on switch" for sperm, said study co-author Jochen Buck, also of Weill Cornell Medicine.
If the enzyme is switched off, the sperm can no longer move, he said.
Across several different tests, the researchers showed that a compound which blocks the enzyme renders mice sperm immobile in 30 minutes to an hour.
The compound was 100 percent effective in preventing pregnancy within the first two hours, dropping to 91 percent in the first three hours, the study said.
After 24 hours, the mice sperm moved like normal again.
- 'Eye-catching advantage' -
The researchers hope are aiming for a single non-hormonal pill that works in under an hour and lasts six to 12 hours, Buck said.
This would be much different to other options under development, such as a hormonal gel currently going through human trials, which all take weeks or months to start and stop working.
No side effects were noticed in the mice. Previous research has suggested that infertile men who had their soluble adenylyl cyclase enzyme permanently switched off had an increased rate of kidney stones.
Buck said this was the result of their enzyme always being off -- which would not be the case for men taking an on demand pill.
The researchers hope to hold the first trials on humans within three years, with a final product possibly up to eight years away, Buck said.
Susan Walker, an expert in contraception at the UK's Anglia Ruskin University not involved in the research, said she was a "little sceptical" a pill would actually make it to market as so many other efforts have fallen short.
But the "eye-catching advantage" of almost immediate effectiveness offered "the possibility of seeing a sexual partner take a pill," she said.
The consultancy Desire Line is working on forecasting the potential uptake of a range of male contraceptive products, according to its founder Steve Kretschmer.
"Initial estimates indicate in the United States that uptake for an on-demand pill which has quick onset of action and 1-2 days duration of action could be about triple that of Viagra when it was initially launched," he told AFP.
Y.Kobayashi--AMWN